Summary.-Serum prolactin concentrations were measured by radioimmunoassays in 98 patients with established carcinoma of breast, 12 patients with cystic mastitis and 10 patients with gynaecomastia and compared with that of age matched normal control women. The serum prolactin levels in the patients with breast cancer, gynaecomastia or cystic mastitis were observed to be similar to that in normal women. It was interesting to note that the levels of prolactin in the Iuteal phase of the cycle were higher than that in the early follicular phase in normal women.
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A CONSIDERABLE body of evidence has accumulated indicating prolactin dependence in experimental mammary cancer (Pearson et al., 1969; Boot, 1970; Yanai and Nagasawa, 1972; Meites et al., 1972) . Several lines of indirect evidence have indicated its role in human breast cancer. Hypophysectomy may lead to remission of metastatic breast cancer in patients whose cancers have shown no response to both oophorectomy and adrenalectomy. Hypophysectomy leads to remission of the disease in some 30% of patients (Atkins et al., 1960) .
It has been assumed that this effect is caused by reduction in mammatropic action ascribed to several anterior pituitary hormones. At the same time, remission of the disease in metastatic breast cancer was observed in some of the patients treated with pituitary stalk section, which generally leads to an increase in prolactin levels (Thurkington, Underwood and Vanwyk, 1971) . Utilizing the stimulation of pentose shunt activity as a criterion for hormone dependence, Salih et al. (1972) compared the hormonal dependence of cultured tumour slices and found prolactin dependence in 20% of 50 breast cancers and 12% also showed affinity for oestrogen.
With the identification of human prolactin as a distinct hormone from human growth hormone and the availability of specific radioimmunoassay for the measurement of circulating prolactin levels, it became possible to explore the role of this hormone in human mammary cancer. Earlier reports by Murray, Mozaffarian and Pearson (1972) have shown that, at least in some of the breast cancer patients, serum prolactin levels are high, whereas Forrest (1972) observed normal levels in breast cancer. Boyns et al. (1973) have indicated that the level of prolactin is not significantly higher in breast cancer patients than in normal controls. These authors suggested that further work is essential before coming to an unequivocal conclusion. Mittra, Hayward and McNeilly (1974) also did not find a difference in mean basal plasma prolactin levels in breast cancer patients and control women. Shiu et al. (1973a) were unable to find elevations in serum lactogenic activity in a group of breast cancer patients by using a sensitive radioreceptor assay (Shiu, Kelly and Friesen, 1973b) . These results correlated well with radioimmunoassay measurements in the same sera . Kwa et al. (1974) found a high prolactin level only in women with a family history of the disease. Recently, Murray and Sarfaty (1974) have reported higher serum prolactin levels in women with advanced cancer of breast.
In the present study specific homologous radioimmunoassay was used to assess circulating prolactin levels in breast cancer. Hunter and Glover (1963) as modified by Midgley (1966) was used to iodinate HPr. To 2 5 ,tg of HPr dissolved in phosphate buffer (plH 7 5), l mCi 1251 and 20 /tg (10 pi) of choramine-T were added as an oxidizing agent and allowed to react for 30 s at room temperature. The reaction was stopped with the addition of 75 jug (35 tul) of sodium metabisulphite. Separation of iodinated hormone from unreacted iodine and damaged hormone was achieved by fractionating the reaction mixture through a column of Sephadex G-75, which had been equilibrated with 50o egg white in phosphate buffer with 0-14 mol/l saline (PBS). Generally 3 radioactive peaks were observed. The radioactive material that was eluted in the void volume represented damaged and aggregated hormone. The radioactive material that was eluted from the column at a position wrhere the native hormone appears was used for the studies. The specific activities of labelled hormone ranged from 100 to 150 ,uCi/uig. To find out the extent of hormone damaged during iodination, 1251 labelled HPr was precipitated by excess 12 of antibody to the same. It was found that 80% of the labelled hormone could be precipitated by the antibody.
A8say.-All assays were carried out by the double antibody technique as described by Midgley (1966) . After the incubation of the antigen with the antiserum and labelled hormone for 48 h at 4°C in a final volume of 0-6 ml, a second antibody (sheep antirabbit gamma globulin) was added. Incubation wvas continued for another 48 h at 4°C. At the end of the incubation period, the contents of each tube were diluted to 3 ml with PBS containing 0-1% gelatin. Finally, bound and free hormones were separated by centrifugation. The tubes were drained and the amount of bound radioactive tracer was determined by gamma ray spectrometry. All serum samples wvere run in duplicate at 2 dose levels. The inter-assay coefficient of variation was 7-8°/, and that of intraassay was less than 5%0. in the luteal phase of the cycle, is higher than in the early follicular phase, the range and mean value being 18-60 ng/ml serum and 43 ± 5 ng respectively in the luteal phase while it varies from 5 to 30 ng and has a mean value of 21 ± 4 ng/ml serum in the early follicular phase.
DISCUSSION
Our studies on 98 breast cancer patients using a homologous radioimmunoassay indicate that the range of prolactin concentration in the above group does not differ from that observed in the normal control subjects. Our results confirm those reported by Boyns and his co-workers who employed heterologous (Boyns et al., 1973) and homologous (Wilson et al., 1974) radioimmunoassays. Mittra et al. (1974) also reported similar observations using homologous assay.
In our studies on control women,i.e. normal menstruating women, we found higher levels of prolactin, ranging from 18 to 60 ng, during the progestational phase (Table) . The above assumption is further supported by the fact that whatever high values of prolactin were obtained in breast cancer patients belonged to the age group 31-50 years, whereas in the case of menopausal and postmenopausal patients none of the values were higher than 30 ng (Fig. 2) . A similar pattern of prolactin was observed in normally menstruating women in whom blood samples were collected on every alternate day of the cycle (Fig. 3) . In contrast, Ehara et al. (1973) , Midgley and Jaffe (1972) and Friesen et al. (1972) have reported that there is no variation in circulating prolactin levels throughout the cycle. However, Vekemans et al. (1972) observed a significant increase of prolactin at mid-cycle and during the luteal phase. Robyn et at. (1973) also indicated that during the luteal phase prolactin values are at a significantly higher mean level than during the follicular phase.
Just on the basis of similar levels of prolactin in cancer and non-cancer patients, it would be wrong to arrive at a conclusion that prolactin has no significant role in mammary tumorigenesis. It is likely that the cases in which the growth of human breast cancer is shown to be dependent on prolactin might be so at a physiological level. Secondly, the hormone concentration available at a cellular level would be of a greater physiological significance. We have shown, in our earlier studies on experimental mammary cancer in mice, that mammary glands of a susceptible strain, namely C3H/Jax, have 6 times higher binding capacity for radioiodinated human placental lactogen (HPL) than that of resistant.,C57 BL strain (Sheth, Ranadive and Shth, 1974) . These results imply the importance of receptor studies. Hobbs et al. (1973) and Furth (1973) have stressed the significance of investigations on the in vitro tests to recognize the prolactin receptors in the mammary gland and its tumour. The occurrence of receptor proteins in certain tissues of the body suggests two important lines of investigation. First, the receptor proteins may provide a mechanism by which target cells trap the hormones and convey them to the nucleus. If this hypothesis is correct, it may be possible to investigate at a molecular level the action of specific hormones within cells. Second, the presence or absence of specific receptors in lesions of the target tissues could provide evidence concerning the hormonal requirement of the lesiotis.
The evidence now suggests that prolactin may be involved in the maintenance, if not initiation, of some human breast cancers. Further critical investigations are required to correlate circulating prolactin levels before and after therapy, and in vitro prolactin dependence, with the clinical response to medical or surgical therapy aimed at lowering prolactin secretion. The fact that some success was achieved in regression of breast cancer by treatment with agents like CB-154 (drugs derived from ergot alkaloids, Schulz et al., 1973) and L-DOPA (Frantz et at., 1973) , which inhibit prolactin secretion, implicates the role of prolactin alone, or acting synergistically with other hormones, in the aetiology of breast cancer. Further studies are warranted.
A recent hypothesis put forward by Mittra et at. (1974) suggests that raised levels of prolactin may not have any pathological effect on mammary epithelium. However, it is possible that an abnormal hormonal environment could alter the sensitivity of mammary epithelial cells to the growth promoting effect of prolactin which might lead to dysplasia and eventual neoplasia. The experimental findings in animals support such a possibility (Mittra, 1974) . Experience collected to date with experimental animals has taught us that the growth, development and function of mammary gland tissues depend upon the interaction of these tissues with many hormones. The importance of an individual hormone has been emphasized from time to time but the fact remains that no single hormone is sufficient when administered at a physiological level. The deviation from the normal hormonal requirement found in abnormal tissue must be measured in terms ofrequirements for a variety of hormones rather than requirement for a single hormone.
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